These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 29915923)

  • 1. Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist.
    Hall S; Isaacs D; Clements JN
    Clin Pharmacokinet; 2018 Dec; 57(12):1529-1538. PubMed ID: 29915923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation.
    Meier JJ
    Front Endocrinol (Lausanne); 2021; 12():645617. PubMed ID: 34248838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists.
    Handelsman Y; Wyne K; Cannon A; Shannon M; Schneider D
    J Manag Care Spec Pharm; 2018 Sep; 24(9-a Suppl):S14-S29. PubMed ID: 30156445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes.
    Tuchscherer RM; Thompson AM; Trujillo JM
    Ann Pharmacother; 2018 Dec; 52(12):1224-1232. PubMed ID: 29932006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
    Cowart K
    Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
    [No Abstract]   [Full Text] [Related]  

  • 6. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
    Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
    J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
    [No Abstract]   [Full Text] [Related]  

  • 7. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
    Doggrell SA
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):371-377. PubMed ID: 29439603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
    Gallwitz B; Giorgino F
    Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
    Wright EE; Aroda VR
    Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
    N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes.
    Andersen A; Knop FK; Vilsbøll T
    Drugs; 2021 Jun; 81(9):1003-1030. PubMed ID: 33964002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist.
    Bucheit JD; Pamulapati LG; Carter N; Malloy K; Dixon DL; Sisson EM
    Diabetes Technol Ther; 2020 Jan; 22(1):10-18. PubMed ID: 31436480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes.
    Seino Y; Terauchi Y; Osonoi T; Yabe D; Abe N; Nishida T; Zacho J; Kaneko S
    Diabetes Obes Metab; 2018 Feb; 20(2):378-388. PubMed ID: 28786547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial.
    Kaku K; Yamada Y; Watada H; Abiko A; Nishida T; Zacho J; Kiyosue A
    Diabetes Obes Metab; 2018 May; 20(5):1202-1212. PubMed ID: 29322610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and Clinical Implications of Oral Semaglutide for Type 2 Diabetes Mellitus.
    Clements JN; Isaacs D; Hartman RE; Gambill K
    Clin Pharmacokinet; 2021 Feb; 60(2):153-163. PubMed ID: 33108617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
    Davies M; Pieber TR; Hartoft-Nielsen ML; Hansen OKH; Jabbour S; Rosenstock J
    JAMA; 2017 Oct; 318(15):1460-1470. PubMed ID: 29049653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes.
    Hedrington MS; Tsiskarishvili A; Davis SN
    Expert Opin Biol Ther; 2018 Mar; 18(3):343-351. PubMed ID: 29431519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
    Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.